Cargando…

Economic Evaluation of Rituximab + Recombinant Human Thrombopoietin vs. Rituximab for the Treatment of Second-Line Idiopathic Thrombocytopenic Purpura in China

Objective: This study aimed to compare the economic evaluation of recombinant human thrombopoietin+rituximab (rhTPO + RTX) vs. RTX as second-line treatment for adult patients with immunologic thrombocytopenic purpura in China. Methods: The Markov model was used in our research. The response rate and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rui, Mingjun, Wang, Yingcheng, Fei, Zhengyang, Shang, Ye, Ma, Aixia, Li, Hongchao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8012846/ https://www.ncbi.nlm.nih.gov/pubmed/33816534 http://dx.doi.org/10.3389/fmed.2021.657539

Ejemplares similares

Rituximab as first-line treatment for acquired thrombotic thrombocytopenic purpura
por: Chen, Haifei, et al.
Publicado: (2017)

Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura
por: Wang, Jiuhe, et al.
Publicado: (2019)

Hypogammaglobulinemia Observed One Year after Rituximab Treatment for Idiopathic Thrombocytopenic Purpura
por: Shoukat, Bilal Ahmad, et al.
Publicado: (2018)

Steroid-Refractory Chronic Idiopathic Thrombocytopenic Purpura Responding to Combination Therapy With Eltrombopag and Rituximab
por: Ahmed, Mohanad, et al.
Publicado: (2020)

Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab
por: Abou-Ismail, Mouhamed Yazan, et al.
Publicado: (2020)

Thrombotic thrombocytopenic purpura treated with rituximab in systemic lupus erythematosus
por: Karimifar, Mansoor
Publicado: (2012)

Common variable immunodeficiency unmasked by treatment of immune thrombocytopenic purpura with Rituximab
por: Mogensen, Trine H, et al.
Publicado: (2013)

Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults
por: Kikuchi, Kayoko, et al.
Publicado: (2015)

A Case of John Cunningham Virus Induced Rhombencephalitis after Rituximab Therapy for Idiopathic Thrombocytopenic Purpura
por: Katragadda, Silpita, et al.
Publicado: (2021)

Long-term Successful Treatment of Rituximab for Steroid-resistant Minimal Change Nephrotic Syndrome and Idiopathic Thrombocytopenic Purpura
por: Nishikawa, Mana, et al.
Publicado: (2019)

Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura: A case report
por: Chaurasiya, Prem Shankar, et al.
Publicado: (2022)

Rituximab Prevents Stroke Recurrences in Atypical Chronic Immune-Mediated Thrombotic Thrombocytopenic Purpura
por: Dupuy, Henry, et al.
Publicado: (2018)

Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab
por: Falter, Tanja, et al.
Publicado: (2018)

Thrombotic Thrombocytopenic Purpura Treated with Rituximab Associated with Primary Sjögren's Syndrome and Primary Hypothyroidism
por: Okumura, Taiki, et al.
Publicado: (2019)

A review of immune thrombocytopenic purpura: focus on the novel thrombopoietin agonists
por: Khan, Meaghan, et al.
Publicado: (2010)

Efficacy and safety of rituximab as second-line therapy in immune thrombocytopenic purpura based on ethnicity: A descriptive study among the Arabic population
por: Ata, Fateen, et al.
Publicado: (2022)

Idiopathic thrombocytopenic purpura
por: Kayal, L., et al.
Publicado: (2014)

Idiopathic Relapsing Thrombotic Thrombocytopenic Purpura with Persistent ADAMTS13 Inhibitor Activity Treated Sequentially with Plasmapheresis, Rituximab, Cyclophosphamide and Splenectomy
por: Musa, Faisal, et al.
Publicado: (2015)

Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report
por: Hoshino, Kouki, et al.
Publicado: (2019)

Slow, but complete, resolution of mitomycin-induced refractory thrombotic thrombocytopenic purpura after rituximab treatment
por: Hong, Mi Jin, et al.
Publicado: (2011)

Thrombotic Thrombocytopenic Purpura in a Patient with Interferon Treated Hepatitis C Successfully Treated with Rituximab
por: Poddar, Nishant, et al.
Publicado: (2013)

Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases
por: Omri, Halima El, et al.
Publicado: (2015)

Successful treatment of plasma exchange-refractory thrombotic thrombocytopenic purpura with rituximab: A case report
por: Chen, Jian, et al.
Publicado: (2020)

A Novel Case of Cytomegalovirus Pneumonia in an Acquired Thrombotic Thrombocytopenic Purpura Patient Treated With Rituximab
por: Kandah, Emad, et al.
Publicado: (2021)

Rituximab therapy for chonic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis
por: Garcia-Chavez, Jaime, et al.
Publicado: (2007)

Combination therapy of rituximab and corticosteroids for patients with refractory chronic immune thrombocytopenic purpura: report of two cases
por: Ling, Yun, et al.
Publicado: (2013)

Positive Response and Increase in ADAMTS13 with Scheduled Rituximab in a Patient with Relapsing Thrombotic Thrombocytopenic Purpura
por: Amer, Bahaa, et al.
Publicado: (2019)

Immune Thrombocytopenic Purpura Complicated by Hepatitis C Virus-related Membranoproliferative Glomerulonephritis after Rituximab Therapy
por: Kubodera, Ai, et al.
Publicado: (2021)

Early treatment of rituximab combined with eltrombopag for secondary thrombocytopenic purpura in rheumatoid arthritis: A case report
por: Zhang, Naidan, et al.
Publicado: (2022)

Octaploidy in idiopathic thrombocytopenic purpura
por: Makroo, R. N., et al.
Publicado: (2011)

Successful Rituximab Treatment in Thrombotic Thrombocytopenic Purpura Patients Complicated by Other Autoimmune Disorders: Two Case Reports
por: Watanabe, Aya, et al.
Publicado: (2021)

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
por: Chen, Pingyu, et al.
Publicado: (2022)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

Immune‐mediated thrombotic thrombocytopenic purpura in a Jehovah’s Witness – Effectiveness of incorporating extracorporeal immunoadsorption to caplacizumab, steroids and rituximab
por: Cardesa‐Salzmann, Teresa Marta, et al.
Publicado: (2022)

P1664: IMPACT OF A PROTOCOL USING RITUXIMAB FOR PREVENTION OF RELAPSE IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP)
por: Marín Sánchez, E., et al.
Publicado: (2022)

New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents
por: Metjian, Ara, et al.
Publicado: (2009)

Comparison of the Long-Term Remission of Rituximab and Conventional Treatment for Acquired Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis
por: Owattanapanich, Weerapat, et al.
Publicado: (2019)

Juvenile Dermatomyositis (JDM) Complicated by Thrombotic Thrombocytopenic Purpura (TTP) and Purtscher's Retinopathy Responsive to Rituximab: Case Report and Literature Review
por: Gullapalli, Keerthi, et al.
Publicado: (2020)

A case of acquired thrombotic thrombocytopenic purpura induced by acute severe hepatitis E: successfully treated by plasma exchange and rituximab
por: Ou, Yingwei, et al.
Publicado: (2023)

Borderline Thrombocytopenia or Mild Idiopathic Thrombocytopenic Purpura?
por: Zimmer, Jacques, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_1f9j3m5alvdutsps6fth8sgjb5